{"ticker": {"uuid": "fc7a1ad2-071e-4d4d-ac46-7cbf33c4acaf", "symbol": "GLMD", "name": "Galmed Pharmaceuticals Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Galmed unveils heart-targeted Aramchol in cardiac fibrosis push", "summary": "Galmed Pharmaceuticals has developed a new lipid nanoparticle (LNP) formulation of its drug Aramchol, designed to selectively target heart tissue for treating cardiac fibrosis. This innovation, in collaboration with Barcode Nanotech, aims to overcome delivery challenges by redire", "url": "https://www.indianpharmapost.com/news/galmed-unveils-heart-targeted-aramchol-in-cardiac-fibrosis-push-20977", "source_name": "Indian Pharma Post", "published_at": "2026-07-19T07:11:56", "published_display": "19 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) tests heart-targeted Aramchol LNPs", "summary": "Galmed Pharmaceuticals (NASDAQ: GLMD) announced a breakthrough in developing a novel lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, that specifically targets heart tissue. This new formulation aims to redirect Aramchol's biodistribution away from the liver ", "url": "https://www.stocktitan.net/sec-filings/GLMD/6-k-galmed-pharmaceuticals-ltd-current-report-foreign-issuer-568d9c675059.html", "source_name": "Stock Titan", "published_at": "2026-07-16T19:40:18", "published_display": "16 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed develops heart-targeted formulation of Aramchol drug", "summary": "Galmed Pharmaceuticals Ltd. announced the development of a heart-targeted formulation of its drug Aramchol, in collaboration with Barcode Nanotech. This new lipid nanoparticle formulation aims to redirect Aramchol from the liver to heart muscle tissue to address cardiac fibrosis,", "url": "https://www.investing.com/news/company-news/galmed-develops-hearttargeted-formulation-of-aramchol-drug-93CH-4795566", "source_name": "Investing.com", "published_at": "2026-07-16T19:11:56", "published_display": "16 Jul 2026 19:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed develops heart-targeted formulation of Aramchol drug By Investing.com", "summary": "Galmed Pharmaceuticals Ltd. announced the development of a heart-targeted formulation of its drug Aramchol, in collaboration with Barcode Nanotech. This new formulation uses lipid nanoparticles to redirect 80-90% of the drug's biodistribution from the liver to heart muscle tissue", "url": "https://ng.investing.com/news/stock-market-news/galmed-develops-hearttargeted-formulation-of-aramchol-drug-93CH-2602812", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T18:11:15", "published_display": "16 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)", "summary": "Galmed (NASDAQ:GLMD) has developed a new cardiac-targeted formulation of Aramchol, its SCD1 inhibitor, using lipid nanoparticles in collaboration with Barcode Nanotech. This innovation aims to redirect the drug from the liver to the heart, expanding its potential application beyo", "url": "https://finance.yahoo.com/healthcare/articles/galmed-develops-cardiac-targeted-aramchol-140526745.html", "source_name": "Market source", "published_at": "2026-07-16T14:05:00", "published_display": "16 Jul 2026 14:05", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed's Aramchol Formulation Redirects Drug Toward Heart Tissue", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQM29fb2dfbHRod1dwM2U2ZUJzc2hLTmpCYVFVU2FCTG5tMFpiVE5VajE1Z1pJVm1UeDBkWmxJM0pybG84eGR2X1BDYk9Tcnp3WEdhLURJYzlhWkt4ZlhzNmMwLUN6UWVfSlpJOHlvVFJMS3M2dHVEQ053S3RQWm5xTVBVT0ozRGpTanBmdTNVSWJoczROdUNmWGp5U1ZZM3N6MkYtWVRrdTZCamxMR3R2MV84SjR0ZXNNNGJOSGh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T11:30:00+00:00", "published_display": "16 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol", "summary": "Galmed Pharmaceuticals Ltd. has announced the development of a new lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, designed for targeted delivery to the heart. This breakthrough, developed in collaboration with Barcode Nanotech, aims to redirect Aramchol's e", "url": "https://www.prnewswire.com/news-releases/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-targeted-formulation-of-its-scd1-inhibitor-aramchol-302827443.html", "source_name": "PR Newswire", "published_at": "2026-07-16T11:10:22", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals (GLMD) Sheds 4.75% as Biotech Volatility Pressures Near Support - Price Action Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNWWd0ZUF2cU55R2NrMFZOUTB6OE56SU8xOFV1ZVF2WGxjM1JDQU9iWW5CS1I1YWJ5dzBBcHVOcVJndW5NUmNRNXYtZlJXbWg1YkcyNXFUTVZrTEZGaTZtZF9NSmNEV0s4ejVzMC1xaFduS3p5cEk1Y0FYbGVwME5CN3hySmpmNWczX1NlSjZyX2JVMHIzNGFoUFlfUTNNTF9lUU5fS0s5Mm4wSkd3Vi1MXzY4SXFITE1OWTlyc3Vod3lMZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-14T22:31:18+00:00", "published_display": "14 Jul 2026 22:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition", "summary": "Galmed Pharmaceuticals (GLMD) reported a widened net loss of $1.9 million in Q1 2026, primarily due to increased research and development spending. Despite holding $15.6 million in current assets, the company anticipates needing substantial additional funding for its programs. Po", "url": "https://www.stocktitan.net/sec-filings/GLMD/6-k-galmed-pharmaceuticals-ltd-current-report-foreign-issuer-4ee61b8636d2.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:09:43", "published_display": "08 Jul 2026 20:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals (GLMD) Plunges Nearly 12% as Stock Tests Key Support at $0.54 - Call Resistance", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPRXo3S1VKcFBUVmhDQ0hVaHpNMFlSTlVTWnExSXBUVkEzZjBpQ1FyUFp3Ukkxem1Ta2kyUG1waklBVzJKeUY1Q1pYbTdMeklJS2ZJTXBzVHMteEYxTXAxWnNBa3dlQVk3MGRpdllYR0tmYlBNVFRZaWs4S0ozY0x6ZDVJdFJubHc5YUlJQlpHNFRibnowMmE3dDlFdlR6MXp1NFBpTzBSUDE0Z3pFdHQ1ZnZFZjRRck1BOEM5SVd3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals (Nasdaq:GLMD) - Stock Analysis", "summary": "Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) is a biopharmaceutical company focused on liver diseases, with a market cap of US$3.8 million. The company faces significant risks including volatile share price, projected earnings decline, substantial shareholder dilution, and low reven", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glmd/galmed-pharmaceuticals", "source_name": "Simply Wall Street", "published_at": "2026-07-02T02:09:14", "published_display": "02 Jul 2026 02:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure", "summary": "Galmed Pharmaceuticals has closed its amended all-cash acquisition of Colospan Ltd., substituting a stock issuance with an additional $800,000 in cash, bringing the total cash at closing to $3.3 million. The deal now includes a performance-based earnout of up to $2.0 million and ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GLMD/pressreleases/2600001/galmed-pharmaceuticals-closes-amended-all-cash-colospan-acquisition-with-earnout-structure/", "source_name": "The Globe and Mail", "published_at": "2026-06-27T04:09:55", "published_display": "27 Jun 2026 04:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Ltd. Actuals & Estimates (NASDAQ:GLMD)", "summary": "This article provides an overview of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), covering its stock performance, financial data, and analyst estimates. Key information includes the current stock price, historical highs and lows, market capitalization, upcoming earnings report date", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T23:11:24", "published_display": "26 Jun 2026 23:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLMD Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Galmed Pharmaceuticals Ltd. (GLMD) stock performance, financial data, and analyst ratings. It highlights the stock's recent price decrease, its all-time high and low prices, market capitalization, and upcoming earnings report. The article also", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:20", "published_display": "26 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This article provides a brief overview of the \"Price to sales forward\" metric for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) on the TradingView platform. It indicates that the market was closed with no trades recorded at the time of publication, and it displays a table showing th", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:21", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This article provides a financial statistic for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD). Specifically, it highlights the company's enterprise value to EBIT forward. The article is part of a larger financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:39:45", "published_display": "26 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GPH Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Galmed Pharmaceuticals Ltd. (GPH) stock, including historical price data, upcoming earnings reports, and financial metrics. It highlights that GPH does not pay dividends and details how to track its financial performance and trade its shares.", "url": "https://www.tradingview.com/symbols/FWB-GPH/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T23:11:20", "published_display": "25 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD). It appears to be a financial snapshot or a report from TradingView, providing specific financial data points for the company. The content itself seems to be a ", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:39:20", "published_display": "25 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This article provides the \"Price to Book Forward\" value for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD). It indicates that the specific financial data point was \"Made by humans\" and references the stock's market on TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:20", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This article focuses on the \"Price to earnings forward\" metric for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) as presented on TradingView. It appears to be a financial data point rather than an in-depth analysis, showing the value and changes over a period. The content primarily ", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:07", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This page from TradingView provides financial information for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), specifically focusing on its enterprise value to EBITDA forward. It indicates various data sources and copyrights for the financial information presented.", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T03:39:51", "published_display": "24 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed buys CG-100 maker Colospan, eyes faster EU sales", "summary": "Galmed Pharmaceuticals has completed its acquisition of Colospan, gaining the CE-marked CG-100 device for colorectal procedures, which is commercial-ready in the EU and Israel with a dedicated German OPS code. The restructured deal replaces a $2.0 million share issuance with an $", "url": "https://www.stocktitan.net/news/GLMD/galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-3ubjgiithqzf.html", "source_name": "Stock Titan", "published_at": "2026-06-22T23:40:43", "published_display": "22 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed (NASDAQ: GLMD) closes Colospan acquisition; $3.3M cash, up to $2M earnout", "summary": "Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has finalized its acquisition of Colospan Ltd., a medical device company, with revised financial terms. The deal includes $3.3 million in cash at closing and a performance-based earnout of up to $2 million, replacing a previous plan for ", "url": "https://www.stocktitan.net/sec-filings/GLMD/424b3-galmed-pharmaceuticals-ltd-prospectus-filed-pursuant-to-rule-42-6e25826efee3.html", "source_name": "Stock Titan", "published_at": "2026-06-22T22:11:07", "published_display": "22 Jun 2026 22:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed completes acquisition of medical device firm Colospan", "summary": "Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has finalized its acquisition of Colospan Ltd., a medical device company, following a restructuring of the deal terms. The revised agreement includes an increased cash payment and an earnout structure tied to net sales, aiming to reduce i", "url": "https://www.investing.com/news/company-news/galmed-completes-acquisition-of-medical-device-firm-colospan-93CH-4752283", "source_name": "Investing.com", "published_at": "2026-06-22T21:12:26", "published_display": "22 Jun 2026 21:12", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals finishes restructured Colospan deal", "summary": "Galmed Pharmaceuticals has completed its acquisition of medical device company Colospan, finalizing restructured terms that replaced a $2 million share issuance with an $800,000 cash payment. The deal also includes an earnout of up to $2 million beginning in Q3 2027 and grants Ga", "url": "https://grafa.com/en/news/united-states/galmed-pharmaceuticals-colospan-acquisition-restructured-terms", "source_name": "grafa.com", "published_at": "2026-06-22T15:09:30", "published_display": "22 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/galmed-pharmaceuticals-completes-acquisition-colospan-135523208.html", "source_name": "MT Newswires", "published_at": "2026-06-22T13:55:23+00:00", "published_display": "22 Jun 2026 13:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K Galmed Pharmaceuticals Ltd For: 22 June By Investing.com", "summary": "This article announces that Galmed Pharmaceuticals Ltd. filed a Form 6-K on June 22. The filing is brief, providing only the date and the company name. Galmed Pharmaceuticals Ltd. (GLMD) stock experienced a -2.76% change according to the article's financial data.", "url": "https://ng.investing.com/news/stock-market-news/form-6k-galmed-pharmaceuticals-ltd-for-22-june-93CH-2567318", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T12:10:46", "published_display": "22 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd.", "summary": "Galmed Pharmaceuticals Ltd. has announced restructured acquisition terms for Colospan Ltd. This brief press release from Refinitiv was published via TradingView News. The full details of the restructured terms are not provided in this short article.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA5VJCTX:0-galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-for-colospan-ltd/", "source_name": "TradingView", "published_at": "2026-06-22T12:09:30", "published_display": "22 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition", "summary": "Galmed Pharmaceuticals Ltd. has announced restructured acquisition terms for Colospan Ltd., allowing for the consummation of the acquisition. The revised agreement reduces immediate shareholder dilution by increasing the cash payment and structuring the remaining balance as a ris", "url": "https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-for-colospan-ltd-prioritizing-cg-100-european-commercialization-and-shareholder-value-protection-and-consummation-of-acquisition-302806225.html", "source_name": "PR Newswire", "published_at": "2026-06-22T11:09:30", "published_display": "22 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed (NASDAQ: GLMD) completes Colospan acquisition with cash and earnout", "summary": "Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has finalized its acquisition of Colospan Ltd. under revised financial terms, paying $3.3 million in cash upfront and up to $2.0 million in performance-based earnouts tied to future net sales, rather than issuing shares. This strategic m", "url": "https://www.stocktitan.net/sec-filings/GLMD/6-k-galmed-pharmaceuticals-ltd-current-report-foreign-issuer-8b67cd88f767.html", "source_name": "Stock Titan", "published_at": "2026-06-22T11:09:30", "published_display": "22 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed completes acquisition of medical device firm Colospan By Investing.com", "summary": "Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced the completion of its acquisition of Colospan Ltd., a medical device company, after restructuring deal terms. The acquisition, which involved an increased cash payment and an earnout structure, comes as Galmed's stock has faced ", "url": "https://ng.investing.com/news/stock-market-news/galmed-completes-acquisition-of-medical-device-firm-colospan-93CH-2567332", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T09:10:46", "published_display": "22 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/galmed-pharmaceuticals-acquire-colospan-create-110000241.html", "source_name": "PR Newswire", "published_at": "2026-06-08T11:00:00+00:00", "published_display": "08 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNTG4xaGpmQjE1OHgzQkFoVXRvVXVfaHNJUXAxYWlIS1JSQmlJekVZUFpiT3dfR2xvS3ZvNVJYeWdKZGtRdjdiaXdhNkR4VHZjN044MkZic0NyaEFGX25NRDVnbGFTcFhQaVYyVXJDNlh2RnIzdnNuTWgwUUhHMWtBUzJuMGViQ2dYU04yR0ZISm9VS2U4ZVM2SlNMNA?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed\u2019s $6B bet on Colospan device to ease life after colorectal surgery", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQY0EwS0RyZmVqMVk0YlNIS3dCUWV6UmJQY0xKUlhmUWdCcm9ndlhjNUhNMzVHdWZadmkyZjFVQm11MkFwaXNTeTk5VkxmYTVLd3J6WURoNkotRmdIV3ZXSVJrNy1XR1ZzbFcwQXpyQVNqUnpfTEFVYlFMRWJlY2tZbno1VkE2UkVSZkhkVS10MHhmeFlKX2tPZ25FcnFOeDE2VWJ5WUx4MTZKMllvblhmSTVVWnQza2FSVnZNaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals (NASDAQ: GLMD) files amendment adding auditor consent", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZ3NNOGFRLWExUkhCUEFSS3B5eldsdnpnSERrVktWb2plcGpfbWI4WUZzWVlxMHVWWEVyaFVSUmZ3cUkwblNZdkNvamloV200cUlqdnBuQzBNWVJFYnppRm5jYXJfa21VVk1UQzlRZmVUbDFSUXJfWFU3M3dlb2VEYkpqUG1ocFBHZGdhWFVEQm1NcE1fNlBzN1RUc2VhU2dSMW51eS0xaVVIZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tissue-dynamics-galmed-unveil-unknown-113000515.html", "source_name": "PR Newswire", "published_at": "2026-06-02T11:30:00+00:00", "published_display": "02 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/galmed-announces-results-first-man-113000355.html", "source_name": "PR Newswire", "published_at": "2026-05-14T11:30:00+00:00", "published_display": "14 May 2026 11:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tissue-dynamics-galmed-pharmaceuticals-develop-113000582.html", "source_name": "PR Newswire", "published_at": "2026-05-06T11:30:00+00:00", "published_display": "06 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "20,000 heart organoids: Galmed builds a new fibrosis test bed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPUkk2d0FCMGN3ZFNsc2ZoSFRQRm4yRW1yYVdzWWY0UWFzWVVBZnZkdXg2VE50VHFrdk5WcFVWeXRCQzNuUE81bk5JYU0xRUdOTGRIekxsbHE2UjhzX29zVjFZOWMyRU9YeHJjaUdvWmhoVzBqU0RPTTQ2dnF0c0Y2TjRUZjYxVlpMa3VHTzJVSzRLLV9nZHJFbWdMSlhQcktBYjhtUGplRmtCZ19pekJJUEZZcTBLdDI0ZG5LRFJodS0?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Galmed Pharmaceuticals Maps Future with Aramchol Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQWnphTTR0R29NbHNoVWJldmxCaC1iWGJ1ZlQ1elVpMXQyNk5fNDdNSTI4bGJzOW5SWHRxd1Y4b0ZlR3ZhaFg5V21Ed0tXWGJyb044VEZTd0J0MXJjRWtSV2JReC0zM2lXV0FhdHU3NUxxRFVQaXJNeGlKN09oTElwcnBCQm1OQXY3ZHc?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Stock Soars On Brain-Penetrating Aramchol Formulation - Galmed Pharmaceuticals (NASDAQ:GLMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPWW5YS2hTamtvaVpCUmwzd2FvTzlEeEM2OUpWSmZTMXRCZVRybmJ2OVlmdHRxR3pDQUZHQ2tUNHA2SGRHWjRSMnNneFRPR1F5MHB6NjhleVN3TXNzcHJGcHRXNDFPNWtQZm1FRFJZYmlOVTk2cllwZGZRa0Z0aU1JMXZMbFE0ek9CaWRjUHlqaFJWdGdGakNUVGlYSGNoNEEwNU5hUGVlN0ZDRzZNZ19OV2lQR2RkeTM1eTB2WjFB?oc=5", "source_name": "Benzinga", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Galmed Pharmaceuticals: Is It A Turnaround Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQSHU5aXRoY2dFT3FzWFNVdGhJSlVFN3BEWHJfR2dUd0NjTlJxVzdha2YySVV6bXNZNmgySGdjVXRRMHN6TldpOWdRYkVEUy03emZzMzJ1dWs0eFN6ZXVHTWhzUXN6a2pYd0szLVhXcC0yeTBITFYwZ3FsS0hxNldTa3NuZFFWTkJ6NWc?oc=5", "source_name": "timothysykes.com", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough \u2014 Retail Sees Dilution Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxOVkdxUnYtaWRzYmZDSDFxZ1lsa0hVUmxtNXQtRmZUX25XSmdNNXRjWVB3Z21kamZMUnZxSnR2RUVCQjRKWnBzU0lCU3Y0cy1STmcyU1YzZWJjbHZkTEJfYUVxTnJ5ZVJTZ3ZpWEpuTnROVE1aOVgzWm5XOFdUeXBuWDl3ZUQwNFY3QnNQTW8xVll6SEJBOWtsRGxXRW9FX25CLWxyV3pMYUNJQzNhQmJLMDZVR1Vaa3hzSC02UHlHbl93U0NXaXhIWl83aHluZ2NhaVlKM3ZkTzlQdHFPeVZqa1BzWU5zb0to?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxObGJyY2k3d3pteldfcXRBeERPZDJKZVN3U2NLMmc4Q2NSSHoxLVdGdWQtSDU4VXhuSUo5NktJYjJjZm1WamJEWUNLVnpPNkJfOFdTRGdBQklHdG1PUXhFRXlWYVBUNW1oSTVJb3lUdzgyMFdHZEd5Q2VkZUlZbVdrV1YwTXk5d19Ga1NBb0l3MzViMHNtbWhUOWdhZjBtUncwUC03QWVRMVhtOEdIZlFyWVdESlIwN3hiZWlITUY5ajRESVdjUjM2a3o0M0x6Y0g3UThPMDBoU0RyTVpoYTVDNjlZdWJaSEREOEl3WkVpdzJacTNXdXRyWGtGTQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-08-25T07:00:00+00:00", "published_display": "25 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPaVBFRjRpbFJrUXRUcXRtMENiOUwxeDBNMjhfeGpTTmF2dnN5R08yUUdFQlBQZkpERlEweEQxSm1yNFc0R3Q5Qm5McGtFaG52emNmUHVjNF9BSHNNV20yZV9oQzFZR2FkWHgweUQ5ZDdQZ3ZyM1hFZ0tYYlZGUDhBUXd5d19ZbUgtcnpsOWJmejJHaU9jNzF3TmdnMnpyVzgxcHlsdW96UFpGQ3U1S3NkRlpWc21melpKQXNiRnZ2MnREaTFXVXZsUkVoOXhfTV9UNzlxSVVnWnZOTnRabkwwMXQzWUo0NUE?oc=5", "source_name": "PR Newswire", "published_at": "2025-05-22T07:00:00+00:00", "published_display": "22 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could Galmed Pharmaceuticals Pull Off a Major Comeback?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQaVRWbTd3a09XMzROZm52QXBKSDJnYjV2anFRSEkwckJQcWR0X2RmZlphbVE5WTlmOVVRaUZVNklJdjk5SGhzYlROWjlMVElIWXQ3UUoxa2NoSENVX0VCRnYyb3NnSExpLW5uWHVOS2g4ajBYWld4VndldklkMDN0Q3V5eDBCd1c2eU1Damh3V3M5VmNxVExVVTU5YWNiV05LYzRGOEhzb1RuVzRkc2RRUjFRWTlMQmR1Z0JRX2pvQnlxOEdDUXc?oc=5", "source_name": "timothysykes.com", "published_at": "2024-09-17T07:00:00+00:00", "published_display": "17 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I Buy GLMD (Galmed Pharmaceuticals Ltd.) | AI Analysis, Technical & News Insights", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1GOFVHenB2UWtMTGM2REd1UDdLazd2a2lnMWFHQUVKQVJLX3UxMndydENFTlpKTjMzSHNRdENLVTB5TThCWE1sNDQ1WExiZWZQWTVTeHN0ZVBUXzRVVHl4OVNzWGlNQ1g0VEZUeVlMYjJHTktJN0x3?oc=5", "source_name": "Kavout | AI", "published_at": "2024-02-28T09:31:16+00:00", "published_display": "28 Feb 2024 09:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceu (GLMD) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE4tZnRrVzUwN3NuSk1xRXJ0SDVSRHowMmZ2MEotRDZjYUJCM1N1dDVDMi15NjU2X0VkdUFuY0pWWjJNeVdlTTRuanpGcWtfUQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-16T09:27:08+00:00", "published_display": "16 Sep 2020 09:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNWXZiYkxESnZTUGdqcDJjXzN2SEduQXItX19VZmRhY2w0Qm1XQkVZTHp6OFVWYWpURHNmdjBPSkE5b0w1dEpxWk52cGg1U3E3YU1QT0FCaVRIdVJ4SGN5SzJsaDBVNmU5NkU5THVMS3FCVjNISFVtX3l4cXJSRUZ6ZHRxNFdHYlBTekJRTHk5c19meW5yY1N2ek43dmJFOFAxZGEybFl6LXowbzdaaFJlcTVIdjAweU1hdGJRcjgtTk9pTUE5WURKU19SdVF3STJSeWc?oc=5", "source_name": "PR Newswire", "published_at": "2018-06-18T07:00:00+00:00", "published_display": "18 Jun 2018 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Galmed unveils heart-targeted Aramchol in cardiac fibrosis push", "summary": "Galmed Pharmaceuticals has developed a new lipid nanoparticle (LNP) formulation of its drug Aramchol, designed to selectively target heart tissue for treating cardiac fibrosis. This innovation, in collaboration with Barcode Nanotech, aims to overcome delivery challenges by redire", "url": "https://www.indianpharmapost.com/news/galmed-unveils-heart-targeted-aramchol-in-cardiac-fibrosis-push-20977", "source_name": "Indian Pharma Post", "published_at": "2026-07-19T07:11:56", "published_display": "19 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) tests heart-targeted Aramchol LNPs", "summary": "Galmed Pharmaceuticals (NASDAQ: GLMD) announced a breakthrough in developing a novel lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, that specifically targets heart tissue. This new formulation aims to redirect Aramchol's biodistribution away from the liver ", "url": "https://www.stocktitan.net/sec-filings/GLMD/6-k-galmed-pharmaceuticals-ltd-current-report-foreign-issuer-568d9c675059.html", "source_name": "Stock Titan", "published_at": "2026-07-16T19:40:18", "published_display": "16 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed develops heart-targeted formulation of Aramchol drug", "summary": "Galmed Pharmaceuticals Ltd. announced the development of a heart-targeted formulation of its drug Aramchol, in collaboration with Barcode Nanotech. This new lipid nanoparticle formulation aims to redirect Aramchol from the liver to heart muscle tissue to address cardiac fibrosis,", "url": "https://www.investing.com/news/company-news/galmed-develops-hearttargeted-formulation-of-aramchol-drug-93CH-4795566", "source_name": "Investing.com", "published_at": "2026-07-16T19:11:56", "published_display": "16 Jul 2026 19:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed develops heart-targeted formulation of Aramchol drug By Investing.com", "summary": "Galmed Pharmaceuticals Ltd. announced the development of a heart-targeted formulation of its drug Aramchol, in collaboration with Barcode Nanotech. This new formulation uses lipid nanoparticles to redirect 80-90% of the drug's biodistribution from the liver to heart muscle tissue", "url": "https://ng.investing.com/news/stock-market-news/galmed-develops-hearttargeted-formulation-of-aramchol-drug-93CH-2602812", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T18:11:15", "published_display": "16 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)", "summary": "Galmed (NASDAQ:GLMD) has developed a new cardiac-targeted formulation of Aramchol, its SCD1 inhibitor, using lipid nanoparticles in collaboration with Barcode Nanotech. This innovation aims to redirect the drug from the liver to the heart, expanding its potential application beyo", "url": "https://finance.yahoo.com/healthcare/articles/galmed-develops-cardiac-targeted-aramchol-140526745.html", "source_name": "Market source", "published_at": "2026-07-16T14:05:00", "published_display": "16 Jul 2026 14:05", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed's Aramchol Formulation Redirects Drug Toward Heart Tissue", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQM29fb2dfbHRod1dwM2U2ZUJzc2hLTmpCYVFVU2FCTG5tMFpiVE5VajE1Z1pJVm1UeDBkWmxJM0pybG84eGR2X1BDYk9Tcnp3WEdhLURJYzlhWkt4ZlhzNmMwLUN6UWVfSlpJOHlvVFJMS3M2dHVEQ053S3RQWm5xTVBVT0ozRGpTanBmdTNVSWJoczROdUNmWGp5U1ZZM3N6MkYtWVRrdTZCamxMR3R2MV84SjR0ZXNNNGJOSGh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T11:30:00+00:00", "published_display": "16 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol", "summary": "Galmed Pharmaceuticals Ltd. has announced the development of a new lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, designed for targeted delivery to the heart. This breakthrough, developed in collaboration with Barcode Nanotech, aims to redirect Aramchol's e", "url": "https://www.prnewswire.com/news-releases/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-targeted-formulation-of-its-scd1-inhibitor-aramchol-302827443.html", "source_name": "PR Newswire", "published_at": "2026-07-16T11:10:22", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals (GLMD) Sheds 4.75% as Biotech Volatility Pressures Near Support - Price Action Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNWWd0ZUF2cU55R2NrMFZOUTB6OE56SU8xOFV1ZVF2WGxjM1JDQU9iWW5CS1I1YWJ5dzBBcHVOcVJndW5NUmNRNXYtZlJXbWg1YkcyNXFUTVZrTEZGaTZtZF9NSmNEV0s4ejVzMC1xaFduS3p5cEk1Y0FYbGVwME5CN3hySmpmNWczX1NlSjZyX2JVMHIzNGFoUFlfUTNNTF9lUU5fS0s5Mm4wSkd3Vi1MXzY4SXFITE1OWTlyc3Vod3lMZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-14T22:31:18+00:00", "published_display": "14 Jul 2026 22:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition", "summary": "Galmed Pharmaceuticals (GLMD) reported a widened net loss of $1.9 million in Q1 2026, primarily due to increased research and development spending. Despite holding $15.6 million in current assets, the company anticipates needing substantial additional funding for its programs. Po", "url": "https://www.stocktitan.net/sec-filings/GLMD/6-k-galmed-pharmaceuticals-ltd-current-report-foreign-issuer-4ee61b8636d2.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:09:43", "published_display": "08 Jul 2026 20:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals (GLMD) Plunges Nearly 12% as Stock Tests Key Support at $0.54 - Call Resistance", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPRXo3S1VKcFBUVmhDQ0hVaHpNMFlSTlVTWnExSXBUVkEzZjBpQ1FyUFp3Ukkxem1Ta2kyUG1waklBVzJKeUY1Q1pYbTdMeklJS2ZJTXBzVHMteEYxTXAxWnNBa3dlQVk3MGRpdllYR0tmYlBNVFRZaWs4S0ozY0x6ZDVJdFJubHc5YUlJQlpHNFRibnowMmE3dDlFdlR6MXp1NFBpTzBSUDE0Z3pFdHQ1ZnZFZjRRck1BOEM5SVd3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals (Nasdaq:GLMD) - Stock Analysis", "summary": "Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) is a biopharmaceutical company focused on liver diseases, with a market cap of US$3.8 million. The company faces significant risks including volatile share price, projected earnings decline, substantial shareholder dilution, and low reven", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glmd/galmed-pharmaceuticals", "source_name": "Simply Wall Street", "published_at": "2026-07-02T02:09:14", "published_display": "02 Jul 2026 02:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure", "summary": "Galmed Pharmaceuticals has closed its amended all-cash acquisition of Colospan Ltd., substituting a stock issuance with an additional $800,000 in cash, bringing the total cash at closing to $3.3 million. The deal now includes a performance-based earnout of up to $2.0 million and ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GLMD/pressreleases/2600001/galmed-pharmaceuticals-closes-amended-all-cash-colospan-acquisition-with-earnout-structure/", "source_name": "The Globe and Mail", "published_at": "2026-06-27T04:09:55", "published_display": "27 Jun 2026 04:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Ltd. Actuals & Estimates (NASDAQ:GLMD)", "summary": "This article provides an overview of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), covering its stock performance, financial data, and analyst estimates. Key information includes the current stock price, historical highs and lows, market capitalization, upcoming earnings report date", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T23:11:24", "published_display": "26 Jun 2026 23:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLMD Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Galmed Pharmaceuticals Ltd. (GLMD) stock performance, financial data, and analyst ratings. It highlights the stock's recent price decrease, its all-time high and low prices, market capitalization, and upcoming earnings report. The article also", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:20", "published_display": "26 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This article provides a brief overview of the \"Price to sales forward\" metric for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) on the TradingView platform. It indicates that the market was closed with no trades recorded at the time of publication, and it displays a table showing th", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:21", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This article provides a financial statistic for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD). Specifically, it highlights the company's enterprise value to EBIT forward. The article is part of a larger financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:39:45", "published_display": "26 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GPH Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Galmed Pharmaceuticals Ltd. (GPH) stock, including historical price data, upcoming earnings reports, and financial metrics. It highlights that GPH does not pay dividends and details how to track its financial performance and trade its shares.", "url": "https://www.tradingview.com/symbols/FWB-GPH/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T23:11:20", "published_display": "25 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD). It appears to be a financial snapshot or a report from TradingView, providing specific financial data points for the company. The content itself seems to be a ", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:39:20", "published_display": "25 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This article provides the \"Price to Book Forward\" value for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD). It indicates that the specific financial data point was \"Made by humans\" and references the stock's market on TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:20", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This article focuses on the \"Price to earnings forward\" metric for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) as presented on TradingView. It appears to be a financial data point rather than an in-depth analysis, showing the value and changes over a period. The content primarily ", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:07", "published_display": "25 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Galmed Pharmaceuticals Ltd. \u2013 NASDAQ:GLMD", "summary": "This page from TradingView provides financial information for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), specifically focusing on its enterprise value to EBITDA forward. It indicates various data sources and copyrights for the financial information presented.", "url": "https://www.tradingview.com/symbols/NASDAQ-GLMD/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T03:39:51", "published_display": "24 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed buys CG-100 maker Colospan, eyes faster EU sales", "summary": "Galmed Pharmaceuticals has completed its acquisition of Colospan, gaining the CE-marked CG-100 device for colorectal procedures, which is commercial-ready in the EU and Israel with a dedicated German OPS code. The restructured deal replaces a $2.0 million share issuance with an $", "url": "https://www.stocktitan.net/news/GLMD/galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-3ubjgiithqzf.html", "source_name": "Stock Titan", "published_at": "2026-06-22T23:40:43", "published_display": "22 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed (NASDAQ: GLMD) closes Colospan acquisition; $3.3M cash, up to $2M earnout", "summary": "Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has finalized its acquisition of Colospan Ltd., a medical device company, with revised financial terms. The deal includes $3.3 million in cash at closing and a performance-based earnout of up to $2 million, replacing a previous plan for ", "url": "https://www.stocktitan.net/sec-filings/GLMD/424b3-galmed-pharmaceuticals-ltd-prospectus-filed-pursuant-to-rule-42-6e25826efee3.html", "source_name": "Stock Titan", "published_at": "2026-06-22T22:11:07", "published_display": "22 Jun 2026 22:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed completes acquisition of medical device firm Colospan", "summary": "Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has finalized its acquisition of Colospan Ltd., a medical device company, following a restructuring of the deal terms. The revised agreement includes an increased cash payment and an earnout structure tied to net sales, aiming to reduce i", "url": "https://www.investing.com/news/company-news/galmed-completes-acquisition-of-medical-device-firm-colospan-93CH-4752283", "source_name": "Investing.com", "published_at": "2026-06-22T21:12:26", "published_display": "22 Jun 2026 21:12", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals finishes restructured Colospan deal", "summary": "Galmed Pharmaceuticals has completed its acquisition of medical device company Colospan, finalizing restructured terms that replaced a $2 million share issuance with an $800,000 cash payment. The deal also includes an earnout of up to $2 million beginning in Q3 2027 and grants Ga", "url": "https://grafa.com/en/news/united-states/galmed-pharmaceuticals-colospan-acquisition-restructured-terms", "source_name": "grafa.com", "published_at": "2026-06-22T15:09:30", "published_display": "22 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/galmed-pharmaceuticals-completes-acquisition-colospan-135523208.html", "source_name": "MT Newswires", "published_at": "2026-06-22T13:55:23+00:00", "published_display": "22 Jun 2026 13:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K Galmed Pharmaceuticals Ltd For: 22 June By Investing.com", "summary": "This article announces that Galmed Pharmaceuticals Ltd. filed a Form 6-K on June 22. The filing is brief, providing only the date and the company name. Galmed Pharmaceuticals Ltd. (GLMD) stock experienced a -2.76% change according to the article's financial data.", "url": "https://ng.investing.com/news/stock-market-news/form-6k-galmed-pharmaceuticals-ltd-for-22-june-93CH-2567318", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T12:10:46", "published_display": "22 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd.", "summary": "Galmed Pharmaceuticals Ltd. has announced restructured acquisition terms for Colospan Ltd. This brief press release from Refinitiv was published via TradingView News. The full details of the restructured terms are not provided in this short article.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA5VJCTX:0-galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-for-colospan-ltd/", "source_name": "TradingView", "published_at": "2026-06-22T12:09:30", "published_display": "22 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition", "summary": "Galmed Pharmaceuticals Ltd. has announced restructured acquisition terms for Colospan Ltd., allowing for the consummation of the acquisition. The revised agreement reduces immediate shareholder dilution by increasing the cash payment and structuring the remaining balance as a ris", "url": "https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-for-colospan-ltd-prioritizing-cg-100-european-commercialization-and-shareholder-value-protection-and-consummation-of-acquisition-302806225.html", "source_name": "PR Newswire", "published_at": "2026-06-22T11:09:30", "published_display": "22 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed (NASDAQ: GLMD) completes Colospan acquisition with cash and earnout", "summary": "Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has finalized its acquisition of Colospan Ltd. under revised financial terms, paying $3.3 million in cash upfront and up to $2.0 million in performance-based earnouts tied to future net sales, rather than issuing shares. This strategic m", "url": "https://www.stocktitan.net/sec-filings/GLMD/6-k-galmed-pharmaceuticals-ltd-current-report-foreign-issuer-8b67cd88f767.html", "source_name": "Stock Titan", "published_at": "2026-06-22T11:09:30", "published_display": "22 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed completes acquisition of medical device firm Colospan By Investing.com", "summary": "Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced the completion of its acquisition of Colospan Ltd., a medical device company, after restructuring deal terms. The acquisition, which involved an increased cash payment and an earnout structure, comes as Galmed's stock has faced ", "url": "https://ng.investing.com/news/stock-market-news/galmed-completes-acquisition-of-medical-device-firm-colospan-93CH-2567332", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T09:10:46", "published_display": "22 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/galmed-pharmaceuticals-acquire-colospan-create-110000241.html", "source_name": "PR Newswire", "published_at": "2026-06-08T11:00:00+00:00", "published_display": "08 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNTG4xaGpmQjE1OHgzQkFoVXRvVXVfaHNJUXAxYWlIS1JSQmlJekVZUFpiT3dfR2xvS3ZvNVJYeWdKZGtRdjdiaXdhNkR4VHZjN044MkZic0NyaEFGX25NRDVnbGFTcFhQaVYyVXJDNlh2RnIzdnNuTWgwUUhHMWtBUzJuMGViQ2dYU04yR0ZISm9VS2U4ZVM2SlNMNA?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed\u2019s $6B bet on Colospan device to ease life after colorectal surgery", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQY0EwS0RyZmVqMVk0YlNIS3dCUWV6UmJQY0xKUlhmUWdCcm9ndlhjNUhNMzVHdWZadmkyZjFVQm11MkFwaXNTeTk5VkxmYTVLd3J6WURoNkotRmdIV3ZXSVJrNy1XR1ZzbFcwQXpyQVNqUnpfTEFVYlFMRWJlY2tZbno1VkE2UkVSZkhkVS10MHhmeFlKX2tPZ25FcnFOeDE2VWJ5WUx4MTZKMllvblhmSTVVWnQza2FSVnZNaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals (NASDAQ: GLMD) files amendment adding auditor consent", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZ3NNOGFRLWExUkhCUEFSS3B5eldsdnpnSERrVktWb2plcGpfbWI4WUZzWVlxMHVWWEVyaFVSUmZ3cUkwblNZdkNvamloV200cUlqdnBuQzBNWVJFYnppRm5jYXJfa21VVk1UQzlRZmVUbDFSUXJfWFU3M3dlb2VEYkpqUG1ocFBHZGdhWFVEQm1NcE1fNlBzN1RUc2VhU2dSMW51eS0xaVVIZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tissue-dynamics-galmed-unveil-unknown-113000515.html", "source_name": "PR Newswire", "published_at": "2026-06-02T11:30:00+00:00", "published_display": "02 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/galmed-announces-results-first-man-113000355.html", "source_name": "PR Newswire", "published_at": "2026-05-14T11:30:00+00:00", "published_display": "14 May 2026 11:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tissue-dynamics-galmed-pharmaceuticals-develop-113000582.html", "source_name": "PR Newswire", "published_at": "2026-05-06T11:30:00+00:00", "published_display": "06 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "20,000 heart organoids: Galmed builds a new fibrosis test bed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPUkk2d0FCMGN3ZFNsc2ZoSFRQRm4yRW1yYVdzWWY0UWFzWVVBZnZkdXg2VE50VHFrdk5WcFVWeXRCQzNuUE81bk5JYU0xRUdOTGRIekxsbHE2UjhzX29zVjFZOWMyRU9YeHJjaUdvWmhoVzBqU0RPTTQ2dnF0c0Y2TjRUZjYxVlpMa3VHTzJVSzRLLV9nZHJFbWdMSlhQcktBYjhtUGplRmtCZ19pekJJUEZZcTBLdDI0ZG5LRFJodS0?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Maps Future with Aramchol Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQWnphTTR0R29NbHNoVWJldmxCaC1iWGJ1ZlQ1elVpMXQyNk5fNDdNSTI4bGJzOW5SWHRxd1Y4b0ZlR3ZhaFg5V21Ed0tXWGJyb044VEZTd0J0MXJjRWtSV2JReC0zM2lXV0FhdHU3NUxxRFVQaXJNeGlKN09oTElwcnBCQm1OQXY3ZHc?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Stock Soars On Brain-Penetrating Aramchol Formulation - Galmed Pharmaceuticals (NASDAQ:GLMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPWW5YS2hTamtvaVpCUmwzd2FvTzlEeEM2OUpWSmZTMXRCZVRybmJ2OVlmdHRxR3pDQUZHQ2tUNHA2SGRHWjRSMnNneFRPR1F5MHB6NjhleVN3TXNzcHJGcHRXNDFPNWtQZm1FRFJZYmlOVTk2cllwZGZRa0Z0aU1JMXZMbFE0ek9CaWRjUHlqaFJWdGdGakNUVGlYSGNoNEEwNU5hUGVlN0ZDRzZNZ19OV2lQR2RkeTM1eTB2WjFB?oc=5", "source_name": "Benzinga", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals: Is It A Turnaround Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQSHU5aXRoY2dFT3FzWFNVdGhJSlVFN3BEWHJfR2dUd0NjTlJxVzdha2YySVV6bXNZNmgySGdjVXRRMHN6TldpOWdRYkVEUy03emZzMzJ1dWs0eFN6ZXVHTWhzUXN6a2pYd0szLVhXcC0yeTBITFYwZ3FsS0hxNldTa3NuZFFWTkJ6NWc?oc=5", "source_name": "timothysykes.com", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough \u2014 Retail Sees Dilution Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxOVkdxUnYtaWRzYmZDSDFxZ1lsa0hVUmxtNXQtRmZUX25XSmdNNXRjWVB3Z21kamZMUnZxSnR2RUVCQjRKWnBzU0lCU3Y0cy1STmcyU1YzZWJjbHZkTEJfYUVxTnJ5ZVJTZ3ZpWEpuTnROVE1aOVgzWm5XOFdUeXBuWDl3ZUQwNFY3QnNQTW8xVll6SEJBOWtsRGxXRW9FX25CLWxyV3pMYUNJQzNhQmJLMDZVR1Vaa3hzSC02UHlHbl93U0NXaXhIWl83aHluZ2NhaVlKM3ZkTzlQdHFPeVZqa1BzWU5zb0to?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxObGJyY2k3d3pteldfcXRBeERPZDJKZVN3U2NLMmc4Q2NSSHoxLVdGdWQtSDU4VXhuSUo5NktJYjJjZm1WamJEWUNLVnpPNkJfOFdTRGdBQklHdG1PUXhFRXlWYVBUNW1oSTVJb3lUdzgyMFdHZEd5Q2VkZUlZbVdrV1YwTXk5d19Ga1NBb0l3MzViMHNtbWhUOWdhZjBtUncwUC03QWVRMVhtOEdIZlFyWVdESlIwN3hiZWlITUY5ajRESVdjUjM2a3o0M0x6Y0g3UThPMDBoU0RyTVpoYTVDNjlZdWJaSEREOEl3WkVpdzJacTNXdXRyWGtGTQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-08-25T07:00:00+00:00", "published_display": "25 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPaVBFRjRpbFJrUXRUcXRtMENiOUwxeDBNMjhfeGpTTmF2dnN5R08yUUdFQlBQZkpERlEweEQxSm1yNFc0R3Q5Qm5McGtFaG52emNmUHVjNF9BSHNNV20yZV9oQzFZR2FkWHgweUQ5ZDdQZ3ZyM1hFZ0tYYlZGUDhBUXd5d19ZbUgtcnpsOWJmejJHaU9jNzF3TmdnMnpyVzgxcHlsdW96UFpGQ3U1S3NkRlpWc21melpKQXNiRnZ2MnREaTFXVXZsUkVoOXhfTV9UNzlxSVVnWnZOTnRabkwwMXQzWUo0NUE?oc=5", "source_name": "PR Newswire", "published_at": "2025-05-22T07:00:00+00:00", "published_display": "22 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could Galmed Pharmaceuticals Pull Off a Major Comeback?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQaVRWbTd3a09XMzROZm52QXBKSDJnYjV2anFRSEkwckJQcWR0X2RmZlphbVE5WTlmOVVRaUZVNklJdjk5SGhzYlROWjlMVElIWXQ3UUoxa2NoSENVX0VCRnYyb3NnSExpLW5uWHVOS2g4ajBYWld4VndldklkMDN0Q3V5eDBCd1c2eU1Damh3V3M5VmNxVExVVTU5YWNiV05LYzRGOEhzb1RuVzRkc2RRUjFRWTlMQmR1Z0JRX2pvQnlxOEdDUXc?oc=5", "source_name": "timothysykes.com", "published_at": "2024-09-17T07:00:00+00:00", "published_display": "17 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I Buy GLMD (Galmed Pharmaceuticals Ltd.) | AI Analysis, Technical & News Insights", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1GOFVHenB2UWtMTGM2REd1UDdLazd2a2lnMWFHQUVKQVJLX3UxMndydENFTlpKTjMzSHNRdENLVTB5TThCWE1sNDQ1WExiZWZQWTVTeHN0ZVBUXzRVVHl4OVNzWGlNQ1g0VEZUeVlMYjJHTktJN0x3?oc=5", "source_name": "Kavout | AI", "published_at": "2024-02-28T09:31:16+00:00", "published_display": "28 Feb 2024 09:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceu (GLMD) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE4tZnRrVzUwN3NuSk1xRXJ0SDVSRHowMmZ2MEotRDZjYUJCM1N1dDVDMi15NjU2X0VkdUFuY0pWWjJNeVdlTTRuanpGcWtfUQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-16T09:27:08+00:00", "published_display": "16 Sep 2020 09:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNWXZiYkxESnZTUGdqcDJjXzN2SEduQXItX19VZmRhY2w0Qm1XQkVZTHp6OFVWYWpURHNmdjBPSkE5b0w1dEpxWk52cGg1U3E3YU1QT0FCaVRIdVJ4SGN5SzJsaDBVNmU5NkU5THVMS3FCVjNISFVtX3l4cXJSRUZ6ZHRxNFdHYlBTekJRTHk5c19meW5yY1N2ek43dmJFOFAxZGEybFl6LXowbzdaaFJlcTVIdjAweU1hdGJRcjgtTk9pTUE5WURKU19SdVF3STJSeWc?oc=5", "source_name": "PR Newswire", "published_at": "2018-06-18T07:00:00+00:00", "published_display": "18 Jun 2018 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 58, "sentiment_summary": {"positive": 14, "negative": 8, "neutral": 36, "score": 53, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "deals", "label": "Deals and strategy", "weight": 6.05, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 14, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 0.55, "latest_week": "2026-07-17", "one_week_move": -2.5, "four_week_move": -5.9, "twelve_week_move": -12.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.620174, "market_dynamics_buy_signal": false, "relative_strength": -48.65611, "fair_value_gap": -82.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.6635, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.5% over one week, -5.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Stock Titan", "count": 10}, {"label": "PR Newswire", "count": 9}, {"label": "Market source", "count": 7}, {"label": "Investing.com Nigeria", "count": 3}, {"label": "timothysykes.com", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "dars.gov.et", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 11}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.5% over one week, -5.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Galmed unveils heart-targeted Aramchol in cardiac fibrosis push"}], "updated_at": "2026-07-21T14:40:24.835768+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}